To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves Tequin (Gatifloxacin) For Short Course Treatment of Acute Bacterial Exacerbation Of Chronic Bronchitis URL: http://www.pslgroup.com/dg/20CF7E.htm Doctor's Guide November 7, 2001
PRINCETON, NJ -- November 7, 2001 -- Bristol-Myers Squibb Company has announced that Tequin® (gatifloxacin), a broad-spectrum fluoroquinolone antibiotic, has been approved by the U.S. Food and Drug Administration as a short-course (five-day) regimen in the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB). Tequin is already approved for ABECB, acute sinusitis and community-acquired pneumonia.
"We are very impressed that, in our research, Tequin has been shown to be effective in treating acute exacerbation of chronic bronchitis in just five days," commented Mark H. Gotfried, M.D., FCCP, Pulmonary Associates, Phoenix, Arizona. Dr. Gotfried spearheaded the research that demonstrated that a short-course (five-day) regimen of Tequin 400mg QD for ABECB was found to be comparable in clinical cure and microbiologic eradication rates to a standard seven-day regimen of Tequin.
The two most common pathogens that cause ABECB are S. pneumoniae and Haemophilus influenzae. The activity of Tequin against S. pneumoniae and Haemophilus influenzae makes it an ideal agent for short course treatment of acute exacerbation of chronic bronchitis. In addition, Tequin (gatifloxacin) was well tolerated in the study. The study was published in the January 2001 issue of Clinical Therapeutics.
SOURCE: Bristol-Myers Squibb Company --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.